PITTSBURGH, Oct. 2 /CNW/ -- Mylan Inc. (NYSE: MYL) today announced the
appointment of Harry A. (Hal) Korman to the position of President, North
America following the completion of the acquisition of Merck Generics Group
In his new role, Mr. Korman will continue to drive growth and development
of Mylan Pharmaceuticals Inc. (MPI), Mylan's generics business in the U.S. In
addition, he will oversee GenPharm, Inc., the former Canadian subsidiary of
Merck Generics and the fourth largest generics company in Canada, and UDL
Laboratories, Inc., the U.S. leader in unit dose packaging.
Mr. Korman previously served as President of MPI, as well as Senior Vice
President of Mylan Laboratories Inc. Since joining Mylan through its
acquisition of UDL Laboratories in 1996, he has served the Company in several
capacities of increasing responsibility, including President of UDL and Vice
President of Sales and Marketing for MPI.
Mylan Vice Chairman and CEO Robert J. Coury commented: "Hal has played a
critical role in our success to date and is a key member of our management
team. He has been instrumental in building Mylan into the leader in quality
generics in the U.S. that we are today. Since Hal's appointment as President
of MPI, he has proven his ability to meet or exceed every objective set for
him and he will certainly rise to these new responsibilities. By bringing
these North American businesses together under Hal's leadership, we will be
best placed to identify and execute on growth and synergy opportunities in the
region. I am confident that we will continue to go from strength to strength
in North America."
Mr. Korman said: "It's been an honor to be part of Mylan for the last 20
years as the company has grown from a leader in the U.S. to a new global
leader in generics and specialty pharmaceuticals. I am also proud to be part
of a management team that truly shares one vision for the new Mylan. As we
look ahead to the future, there have never been greater opportunities to take
the company forward and continue to provide the best quality products and
service to our customers."
Mylan Inc. is one of the world's leading quality generic and specialty
pharmaceutical companies. The Company offers one of the industry's broadest
and highest quality product portfolios, a robust product pipeline and a global
commercial footprint through operations in more than 90 countries. Through
its controlling interest in Matrix Laboratories Limited, Mylan has direct
access to one of the largest active pharmaceutical ingredient (API)
manufacturers in the world. Dey L.P., Mylan's fully integrated specialty
business, provides the Company with innovative and diversified opportunities
in the respiratory and allergy therapeutic areas.
For more information about Mylan, please visit www.mylan.com.
For further information:
For further information: Kris King, Mylan, Inc., +1-724-514-1800 Web